Orally administered Gastrin‐SiO2 microspheres (Chinese patent number: ZL 2021 1 0223615.0), by stimulating intestinal CCKBR, may provide an effective strategy in the treatment of T2D in a mouse model by inhibiting the PI3K/Akt/eIF4B‐mediated SGLT1/GLUT2 pathway. Here, SLC5A1 is linked to type 2 diabetes mellitus.